Deals in Depth: April 2010

01 Jun 2010

Executive Summary

April's leaders included a $165mm deal that gave Allergan rights to Serenity's late-stage Ser120 for nocturia. Medtronic offered $313mm to buy cardiac device company ATS Medical. Of the nearly $1bn in IPO money, 85% came from one company - Shenzhen Hepalink Pharma. Follow-on dollars on the device side were strong, with two companies bringing over $70mm, while both biopharma and device companies together raised $568mm in private financings.

Already Registered? Sign in to continue reading.

New to In Vivo? Start a free trial today!

Table
View full table

Topics

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Medical Device

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

IV003508

Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

IV003508

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Deals in Depth: April 2010

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Deals in Depth: April 2010

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert